Ponatinib

ICLUSIG

Open Ponatinib in the interactive console ↗

Pronunciation: poe-NA-ti-nib (eye-KLOO-sig)

Ponatinib ballicule: receptor binding, kinetics and half-life diagram — Mechanism of action: Ponatinib ballicule

Ponatinib ICLUSIG mascot mnemonic cartoon — Visual mnemonic: Ponatinib mascot
**“Inclusive Pony tail nibbler”**

What it isOral pan-BCR-ABL tyrosine-kinase inhibitor for resistant CML and Ph-positive ALL.

Why this oneIt retains activity against the T315I gatekeeper mutation that defeats most other BCR-ABL inhibitors.

What limits itArterial occlusion, venous thrombosis, heart failure, and hepatotoxicity demand aggressive cardiovascular selection and monitoring.

Ponatinib molecular structure (skeletal formula) — Molecular structure: Ponatinib

Ponatinib prescription history

Animated chart of estimated U.S. prescriptions per year, Tyrosine kinase inhibitors (2001–2026). Ponatinib enters in 2012 (estimated).

Classes and tags

Clinical profile

Therapeutic safety burden4 / 4

Overdose danger2 / 4

Weight-gain liability1 / 4

Sedation liability0 / 4

QT / Torsades1 / 4

Direct muscarinic antagonism0 / 4

Embryofetal risk2 / 4

Legacy pregnancy categoryD

Defining liabilityArterial occlusion and multiorgan toxicity

FDA label

Read the full label on DailyMed ↗

BOXED WARNING Arterial occlusive events incl. fatal MI/stroke (in patients with and without CV risk factors, incl. age ≤50), venous thromboembolic events, heart failure incl. fatal, and hepatotoxicity/liver failure — monitor; interrupt or discontinue based on severity

FDA dosing	Population	Start	Target	Max
Newly diagnosed Ph+ ALL (with chemotherapy)	adults	30 mg QD	reduce to 15 mg QD upon MRD-negative (≤0.01% BCR::ABL1/ABL1) CR at end of induction; continue up to 20 cycles	30 mg QD
Ph+ ALL monotherapy (no other kinase inhibitors indicated, or T315I-positive)	adults	45 mg QD	45 mg QD until loss of response or unacceptable toxicity (optimal dose not identified)	45 mg QD
CP-CML	adults	45 mg QD	reduce to 15 mg QD upon ≤1% BCR::ABL1IS; may re-escalate to previously tolerated 30 or 45 mg QD on loss of response	45 mg QD
AP-CML and BP-CML	adults	45 mg QD	45 mg QD until loss of response or unacceptable toxicity; consider dose reduction in AP-CML on major cytogenetic response	45 mg QD

Renal Undefined

Hepatic Monotherapy (CP/AP/BP-CML, Ph+ ALL): reduce starting dose 45→30 mg QD for pre-existing impairment (Child-Pugh A, B, or C). Newly diagnosed Ph+ ALL: no adjustment for Child-Pugh A; monitor closely in B/C

Instructions

With or without food; swallow tablets whole — do not crush, break, cut, or chew
Missed dose: take next dose at regularly scheduled time next day
Consider discontinuing if no response by 3 months (monotherapy indications)
Toxicity dose reductions: CP-CML 45→30→15→10 mg QD; AP/BP-CML and Ph+ ALL monotherapy 45→30→15 mg QD; newly diagnosed Ph+ ALL 30→15→10 mg QD; discontinue if lowest step not tolerated
If strong CYP3A inhibitor unavoidable: 45→30, 30→15, 15→10 mg QD (avoid if on 10 mg)
Withhold ≥1 week before elective surgery; do not give for ≥2 weeks after major surgery and until adequate wound healing

Available strengths

tab 10, 15, 30, 45 mg

Cautions

Arterial occlusive events, VTE, heart failure, hepatotoxicity (boxed)
Hypertension incl. renal artery stenosis — monitor BP; interrupt/reduce/stop if not controlled
Pancreatitis and lipase elevation — monitor serum lipase
Peripheral and cranial neuropathy
Ocular toxicity — comprehensive eye exams at baseline and periodically
Hemorrhage
Fluid retention
Cardiac arrhythmias
Myelosuppression — CBC every 2 weeks x3 months, then monthly
Tumor lysis syndrome — hydrate, correct uric acid before starting
Reversible posterior leukoencephalopathy syndrome
Impaired wound healing and GI perforation

Adverse reactions

Single agent (>20%): rash, arthralgia, abdominal pain, fatigue, headache, constipation, hypertension, dry skin, hepatotoxicity, fluid retention/edema, pyrexia, pancreatitis/lipase elevation, nausea, hemorrhage, anemia, arterial occlusive events, cardiac arrhythmias
Grade 3/4 labs (>20%): decreased platelets, neutrophils, WBC

Pregnancy Can cause fetal harm — adverse developmental effects in rats at exposures below human exposure at 45 mg/day

Lactation Do not breastfeed during treatment and for 1 week after last dose

Cost

Ponatinib (ICLUSIG)

Strength		#/mo	CostPlus
10 mg	tab	30 qd	not offered
15 mg	tab	30 qd	not offered
30 mg	tab	30 qd	not offered
45 mg	tab	30 qd	not offered

NADAC is a voluntary CMS survey of what retail community pharmacies pay for the drugs they stock. Ponatinib is dispensed outside retail pharmacies, so it rarely appears on surveyed invoices.

Open Ponatinib in the interactive console ↗

Self-check

Ponatinib: Which gatekeeper mutation does it retain activity against?
T315I.
Ponatinib: What arterial complication requires careful cardiovascular selection?
Arterial occlusion.